Preventing epithelial apoptosis

Preventing epithelial apoptosis is a therapeutic strategy rather than a single molecular target, focusing on the preservation of epithelial barrier integrity in various organ systems. Epithelial cells serve as a primary defense against environmental insults, and their loss through programmed cell death is a central pathogenic mechanism in diseases such as inflammatory bowel disease (IBD), acute lung injury, and acute kidney injury (Source: NCBI, PMC4026547). This objective is typically pursued by inhibiting pro-apoptotic mediators like TNF-alpha or caspases, or by stimulating pro-survival pathways via growth factors like Keratinocyte Growth Factor (KGF) (Source: PubMed, 15155605). While effective in reducing acute tissue damage, the long-term inhibition of apoptosis carries a significant risk of oncogenesis, as it may allow the survival and proliferation of cells with genomic instability (Source: Nature Reviews Molecular Cell Biology). Therefore, drugs targeting this process must be carefully evaluated for their impact on tissue homeostasis and cancer risk.

Other names

Epithelial apoptosis inhibitionAnti-apoptotic epithelial therapyEpithelial cell death prevention

The mechanism involves the modulation of intracellular signaling pathways to prevent programmed cell death in epithelial tissues. This can be achieved through the inhibition of extrinsic apoptotic pathways (e.g., blocking TNF-alpha or Fas ligand), the inhibition of intrinsic pathways (e.g., stabilizing the mitochondrial membrane or inhibiting p53), or the direct inhibition of executioner caspases like Caspase-3 (Source: PubMed, 21885156). Additionally, activating pro-survival pathways such as the PI3K/AKT or MAPK/ERK pathways via growth factor receptors (e.g., FGFR2b) can counteract apoptotic stimuli (Source: Journal of Clinical Investigation, 113(1): 12–14).